98%
921
2 minutes
20
Purpose: Both ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake and epidermal growth factor receptor (EGFR) status are prognostic variables of colorectal cancer (CRC). The aim of this study was to investigate a possible association between ¹⁸F-FDG uptake on preoperative positron emission tomography/computed tomography (PET/CT) and EGFR status in primary CRC.
Materials And Methods: Records of 132 patients (66 men and 66 women; mean age=67.1±11.1 years) who underwent ¹⁸F-FDG PET/CT for CRC staging and subsequent bowel resection were reviewed. In primary lesions, ¹⁸F-FDG uptake was semiquantitatively evaluated in terms of maximum standardized uptake value (SUVmax), and EGFR status was determined by immunohistochemistry. Associations of clinicopathological parameters and EGFR status were analyzed by Pearson's chi-square test, multiple logistic regression, and receiver operating characteristic curves.
Results: Eighty-six patients (65.2%) showed EGFR expression. SUVmax was significantly lower in EGFR-negative tumors than in EGFR-expressing tumors (10.0±4.2 vs. 12.1±2.1; p=0.012). It was the only significant parameter correlated with EGFR expression (odds ratio=2.457; relative risk=2.013; p=0.038). At the SUVmax threshold of 7.5, the sensitivity and specificity for predicting EGFR expression were 84.9% and 40.4%, respectively (area under the curve=0.624; p=0.019).
Conclusion: Preoperative ¹⁸F-FDG uptake is slightly correlated with EGFR status in primary CRC. Preoperative SUVmax of ¹⁸F-FDG may have a limited role in predicting EGFR expression in such tumors because of its poor specificity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696959 | PMC |
http://dx.doi.org/10.3349/ymj.2016.57.1.232 | DOI Listing |
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of nursing, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, China.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are important treatments for EGFR mutant non-small cell lung cancer (NSCLC). However, the first and second generation EGFR-TKI face clinical limitations due to acquired resistance, such as the T790M mutation. Irreversible EGFR-TKI can significantly prolong the survival of patients by enhancing the inhibition of drug-resistant mutations through the covalent binding mechanism.
View Article and Find Full Text PDFInt Urol Nephrol
September 2025
Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Purpose: Living donor kidney transplantation is a critical strategy to address the growing burden of end-stage kidney disease (ESKD) in Malaysia. Whilst living donation is generally safe, concerns remain regarding long-term donor outcomes. This study aimed to evaluate renal function and morbidity changes in living kidney donors 1 year post-donation, and to identify predictors of impaired kidney function.
View Article and Find Full Text PDFEur Radiol
September 2025
Quantitative Imaging Biomarkers in Medicine, Quibim, Valencia, Spain.
Objectives: In non-small cell lung cancer (NSCLC), non-invasive alternatives to biopsy-dependent driver mutation analysis are needed. We reviewed the effectiveness of radiomics alone or with clinical data and assessed the performance of artificial intelligence (AI) models in predicting oncogene mutation status.
Materials And Methods: A PRISMA-compliant literature review for studies predicting oncogene mutation status in NSCLC patients using radiomics was conducted by a multidisciplinary team.
Cell Mol Biol (Noisy-le-grand)
September 2025
Assistant Professor of General Surgery, Department of Surgery, College of Medicine, University of Duhok, Kurdistan Region, Iraq.
Hormonal status and lymphatic invasion are two important prognostic factors among cases of breast cancer. This study aims to assess and evaluate the hormonal receptor status and lymph node involvement among female breast cancer patients in Duhok city, Kurdistan region, Iraq. A retrospective cross-sectional study was conducted, involving 156 diagnosed cases of breast cancer who had undergone surgical treatment and laboratory investigations at Azadi Teaching Hospital and Duhok Private Hospital for 30 months.
View Article and Find Full Text PDFOncol Res
September 2025
The Breast Center, Cancer Hospital of Shantou University Medical College, Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Shantou, 515031, China.
Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide, with significant geographic disparities in its impact. While human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as trastuzumab, have improved outcomes for HER2-positive breast cancer, challenges like therapy resistance persist, highlighting the need for novel treatments. Recent developments in antibody-drug conjugates (ADCs), particularly disitamab vedotin (RC48), show promising efficacy in targeting both HER2-positive and HER2-low expression tumors, warranting further investigation through real-world studies to assess its broader clinical applicability.
View Article and Find Full Text PDF